H.C. Wainwright Comments On Neuralstem Following Presentation At The Annual Symposium On ALS


In a research report issued today, H.C. Wainwright analyst Reni Benjamin maintained a Neutral rating on Neuralstem (NYSE:CUR), as Dr. Glass of Emory University, presented positive longterm follow-up data of a subset of patients from the Phase 1 trial of NSI-566 testing Neuralstem’s human neural stem cells in Amyotrophic Lateral Sclerosis (ALS). No price target was provided.

Benjamin wrote, “The 1200-day data analysis (post stem-cell treatment) revealed that two patients (out of a total of 15 evaluated) maintained the same level of functionality for over three years when evaluated by ALS Functional Rating Scale-Revised (ALSFRS-R) score. In addition, one patient (Ted Harada) demonstrated functional recovery from pre-treatment baseline levels that has been maintained to the present day. Together, the data continue to suggest that NSI-566 treatment can slow the progression of the disease for over three years in ambulatory patients given bilateral injections of NSI-566 cells in the lumbar and cervical spine. Although these data are encouraging and reinforce the potential validity of the treatment paradigm, we continue to be cautious due to the natural heterogeneity of results seen in this patient population.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Reni Benjamin has a total average return of -5.3% and a 26.5% success rate. Benjamin is ranked #3157 out of 3295 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts